Novavax reports Q1 2026 results on May 8 with one of the most extreme short-side setups in the biotech universe — yet a sharp rally into the print has already squeezed a portion of those bears.
The lending market is about as tight as it gets. Availability has collapsed to just 0.73% of short interest, meaning there is less than one share available to borrow for every 135 already lent out. That near-zero availability reflects a borrow market running at full capacity — utilization has been pinned at 100% for much of the past six weeks. Despite that stranglehold on supply, cost to borrow has remained surprisingly subdued, running around 0.94% APR and easing roughly 9% over the past week. Short interest itself is heavy at 29% of free float — ranking in the 2nd percentile of the broader universe on short score rank — and the ORTEX short score has climbed to 82.1 over the past two weeks, among the highest readings for the stock. Yet positions have barely moved in the near term: shorts are up just 1.6% over the past week and have actually contracted about 4.3% over the past month, suggesting bears added early in the spring and have since held rather than pressed. The stock, meanwhile, has surged 17% over the past week and 22% over the past month to $9.36, a move that has handed active short sellers a painful mark-to-market loss.
Options traders are not rushing to buy downside protection. The put/call ratio is 0.54, only marginally above its 20-day average of 0.49 and well short of the 52-week high of 0.85 — a z-score of 0.67 puts this firmly in neutral territory. The absence of heavy put buying is notable given the short setup; it suggests that options participants are not broadly alarmed by the event risk, or that call demand has been keeping pace as momentum traders chase the recent run.
The bull and bear debate runs deep at Novavax. Bulls point to the Pfizer partnership and the Matrix-M adjuvant platform as long-term revenue anchors, with HC Wainwright maintaining a Buy and a $16 target as recently as February. BTIG reaffirmed its Buy and $19 target in January. Bears counter that the company remains unprofitable — last quarter saw a $9.5M net loss on $139.5M in revenue, with revenue down 79% year-on-year — and that reliance on milestone payments and a negative book value create persistent balance-sheet uncertainty. TD Cowen, the most recent mover, lifted its target from $8 to $9 on the day of the print while holding a Hold rating — a cautious upgrade that puts the Street's implied fair value essentially at the current price. JPMorgan remained Underweight with a $6 target as of November, flagging the downside risk. The mean analyst price target of $14 sits well above the current price, but the spread between the most bearish and most bullish targets reflects genuine disagreement about whether the Pfizer royalty stream can compensate for the collapse in direct COVID vaccine revenues.
Institutional ownership adds an interesting wrinkle. Shah Capital holds nearly 9% of shares — and added 1.35 million shares in the quarter ending April 8 — while State Street added 2.3 million shares through April 30. These are not passive accumulations; they represent active conviction building into an already crowded short. Vanguard also added over 1 million shares in Q1. Insider trades over the past 90 days are net positive in shares (though the cash picture is murkier, as several executives sold small tranches in March following stock award grants). The net institutional buying against a near-maxed borrow pool creates a structural tension that the May 8 print will either release or tighten further.
The report is less about any single revenue beat and more about whether management can show the Pfizer partnership is generating durable, predictable cash flows — and whether that is enough to justify a stock trading close to the upper bound of what the most skeptical analysts on the Street are willing to pay.
See the live data behind this article on ORTEX.
Open NVAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
